Meg is passionate about driving change by collaborating with physicians, technology leaders and solution innovators to improve health care. She has served in product development and business development leadership roles at the AMA and most recently is responsible for driving the roadmap of initiatives that support the AMA’s digital health and medicine strategy. In addition, she has led partnerships and innovation related initiatives, such as the inaugural AMA Healthier Nation Innovation Challenge, the establishment of the AMA Interaction Studio at MATTER, the AMA Physician Innovation Network that enables entrepreneurs and physicians to collaborate on the development of new solutions, the AMA Digital Health & Telehealth Implementation Playbook series, AMA Digital Health research and The Telehealth Initiative with collaborators. She participates on the Advisory Board for MATTER, MassChallenge HealthTech, HealthTech Arkansas, Together.Health and as a TEDMed Research Scholar. She also participates on the Editorial Review Board of The Telehealth and Medicine Today Journal.

Meg has spoken at national conferences such as Health 2.0, Connected Health, HLTH, American Telemedicine Association National Conference, AMA State Advocacy Conference and contributes as speaking faculty for Columbia Business School’s Digital Health program curriculum. She has articles published in Health Affairs, Harvard Business Review and Nature Digital Medicine.

Prior to AMA, Meg worked in the Consumer Product & Retail vertical at Capgemini and at SmithBucklin Corporation for various business and health care clients.

Kamal is an industry leader with 15+ years of experience in digital health from a provider perspective, most recently at MassGeneral Brigham, with a background in digital health strategy, product design and clinical research and validation. Kamal has developed and implemented 100+ digital health programs and is widely published in the value digital health can bring to healthcare delivery.

Alyssa Reisner is a Lead Director and Principal at CVS Health Ventures. In her role, she sources, evaluates, and executes investments in innovative health care companies. She has built strategic relationships and executed investments for CVS Health in areas spanning DTx, women’s health, behavioral health, COVID-19 initiatives, and more.

Katie joined AbbVie in May 2021 as a Director of Regulatory Affairs for the newly formed Digital &
Medical Device Team in the Emerging Technology & Combination Product group. In this role, Katie and
her team support internally developed SaMD projects providing regulatory strategy during development
and GRL support prior to global launch. In addition, Katie is the lead Device Regulatory for the ABBV-
RGX-314 partnership between AbbVie and Regen X Bio supporting both key ancillary devices required
for the Subretinal and Suprachoroidal delivery of the biologic.
Prior to joining AbbVie, Katie held a biomedical engineer and lead reviewer position the US FDA Center
for Devices and Radiological Health (CDRH) in the Cardiovascular Device Division (DCD) in the Office of
Device Evaluation (ODE) from 2006 until 2015. In this role she was the lead reviewer for interventional
cardiovascular devices including guidewires, guide catheters, bare metal, drug eluting and bioabsorbable
stents. After completing the Leadership Readiness program in 2015, Katie joined the Office of Orphan
Products Development (OOPD) in the Commissioner’s Office where she led review of the Humanitarian
Use Device (HUD) designations, supported the Pediatric Device Consortium and Orphan Clinical Trials
grants. Her last official role at the Agency took her back to CDRH where she headed the partnership with
the Medical Device Innovation Consortium (MDIC) in the External Partnerships sector and supported
regulatory science project development across multiple initiatives including Digital Health, In Vitro
Diagnostics, Early Feasibility Studies (EFS), Case for Quality and Science of Patient Input.
Katie holds her undergraduate degree from the University of Pittsburgh (cum laude) in Biomedical
Engineering (2004) and her master’s degree from Maquette University and the Medical College of
Wisconsin in Healthcare Technology Management (2005). Katie resides in NW Washington DC with her
husband, Atiq, and twin boys, Isaac and Isaiah.

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Dr. Azizi Seixas is a national and international thought leader in precision and
personalized population health, digital health technology and innovation, and novel
analytical tools like AI and machine learning to tackle our most vexing public health
issues. He is currently Associate Professor of Behavioral Health and Psychology at the
University of Miami Miller School of Medicine, Director of The Media and Innovation Lab
(The MIL), Associate Director of the Center for Translational Sleep and Circadian
Sciences (TSCS) and leading the University of Miami’s Digital Therapeutics vertical in the
Institute of Data Science and Computing. He was selected as an Education Champion by
Amazon Web Services for his innovative work using cloud computing technology and his
advocacy for improving education and recognized by Cell Press, the world’s most
renowned scientific publishing house, as top 100 most inspiring Black scientists in
America.
Dr. Seixas’ mission to make healthcare more equitable for all starts with fundamentally
rethinking the paradigms by which data is transformed into stories that inspire action – from how
academic research institutes engage with underserved, disenfranchised and overlooked
communities, to fostering a new generation of scientific leaders from within these communities
to drive future research and innovative thinking.  The University of Miami shares this bold vision,
and recruited Dr. Seixas to establish The MIL as a hot-bed of investigation, innovation, and
collaboration and to integrate more fully with the communities of South Florida and beyond.
Dr. Seixas’ groundbreaking research broadly focuses on three areas: multilevel determinants of
sleep and cardiovascular disease disparities; long-term health consequences of cardiovascular
disease (CVD) disparities; and, developing adaptive, group-tailored, and personalized behavior
modification interventions, with the use of machine learning analytical tools, to improve health
and well-being.
Dr. Seixas is one of the world’s most recognized and renown voices in sleep health, driving
important conversations regarding sleep medicine and emerging technologies, serving as Vice
Chair for the American Academy of Sleep Medicine (AASM) Committee on AI and Machine
Learning and serving as Conference Chair for the AASM Sleep Disruptors Conference. He is a
member of the Philips International Sleep Advisory Board, leading discussions regarding the
matrix between sleep and chronic disease. Dr. Seixas also serves on the Cardiac Rehabilitation
Board of the American Heart Association.

Whitney is a Director of Clinical Project Management. She oversees the implementation of multiple
clinical trials at Curebase, including some in digital therapeutics. She has worked in the decentralized
trial space for over 5 years and in clinical research for over 10.

Jay Ahlman is Vice President of CPT Coding and Reimbursement Policy and Strategy for the American Medical Association (AMA). Jay joined the AMA in 1999 and has held various roles in healthcare strategy, policy and coding during his tenure.  Since 2008, Jay has led the AMA group responsible for the maintenance of the Current Procedural Terminology (CPT) code set and is the lead staff to the CPT Editorial Panel for the AMA.  During this time Jay has worked with the CPT Editorial Panel to lead many significant changes, including the evolution of CPT Literature Standards and the launch of new CPT coding sections including the Proprietary Laboratory Analyses (PLA) code section.  Jay is also the lead staff to the AMA’s Digital Medicine Payment Advisory Group, which is an advisory body made up of 15 industry experts charged with creating solutions to enable the integration of digital healthcare and telehealth solutions into clinical practice.  Most recently, Jay has been involved in the revision of the CPT Evaluation and Management coding structure and the addition of Remote Physiologic and Remote Therapeutic Monitoring codes to the CPT code set.

Smit J. Patel, PharmD serves as the Strategic Program Lead at the Digital Medicine Society (DiMe), a 501(c)(3) global non-profit organization dedicated to advancing digital medicine to optimize human health. His work focuses on applied approaches to the safe, effective, ethical, and equitable use of digital technologies to advance its evaluation and implementation in clinical research and care delivery. He is an Advisory Board member for the Brown-Lifespan Center for Digital Health and the Digital Therapeutic Alliance (DTA) and serves on advisory committees for digital health program(s) at the Association of Community Cancer Centers (ACCC), American Pharmacists Association (APhA), and HealthXL. He also serves on the steering committee for the APACMed Digital health reimbursement alliance.

Amir is an established neuroscientist specialized in digital medicine and clinical innovation. His strategic vision is empowered by real-world data that enable the discovery of clinical insights otherwise not possible solely based on conventional health records. Amir has boundless passion for accelerating novel therapies and creating a path for better patient experience. He brings an entrepreneurial zeal to the clinical world through disruptive technology and AI analytics from proof of concepts to scale-up solutions. Prior to pharma , Amir was a professor of Pediatrics and Epidemiology at Harvard Medical School and Harvard School of Public Health and served as a PI on numerous clinical trials with 200+ publications and conference presentations.

Dr. Risa Weisberg has devoted her career to developing and scientifically testing scalable interventions for common behavioral health problems. Her mission is to expand the reach of high-quality, science-based behavioral health treatment. She has over two decades of research, clinical, and leadership experience which she now brings to lead the clinical direction and research strategy of BehaVR at Chief Clinical Officer. Risa has a doctoral degree in Clinical Psychology from the University at Albany. She completed a doctoral internship and postdoctoral fellowship at Brown University. She is a Professor of Psychiatry at the Boston University School of Medicine and an Adjunct Professor of Family Medicine at the Alpert Medical School of Brown University. She is an expert in cognitive-behavioral therapy and acceptance and commitment therapies. As a primary care psychologist, Risa has broad experience in treatment development and implementation for common behavioral health problems including anxiety, depression, chronic pain, substance use disorder, and adaptation to living with other chronic medical difficulties. Her research has been funded by the National Institutes of Health, the Patient Centered Outcomes Research Institute, the Veterans Administration, and numerous foundations. Risa is a member of the Scientific Council of the Anxiety and Depression Association of America and a Fellow and former Board Member of the Association for Behavioral and Cognitive Therapies.

Sean Kinsman, DPT serves as the Chief Clinical Officer at RecoveryOne, a leading
digital health innovator dedicated to improving health outcomes for recovery from
musculoskeletal (MSK) injuries of all types and reducing costs. Dr. Kinsman has been
instrumental in driving RecoveryOne’s expansion into clinical care and is the
architect behind their network of clinicians who service patients through their digital
treatment pathways. He is a Board Certified Orthopedic Clinical Specialist.
Prior to joining RecoveryOne, Dr. Kinsman contributed to the world-renowned “MICU
Study” while working in clinical practice at Johns Hopkins Hospital. The study focused
on the early mobilization of medically complicated patients in an intensive care unit
setting. Dr. Kinsman was also a key contributor to Johns Hopkins’ Hemophilia Clinic
and Cystic Fibrosis teams, managing long-term complications in both populations.
Dr. Kinsman’s previous experience also includes serving as part of a multi-
disciplinary team of Stanford physicians where he contributed to the creation of an
innovative, intensive recovery program for patients who developed dependence to
prescription opioids. The program averaged a 76% clinical success rate over six
years.
He previously also served as Clinic Director at Henning and Cole, a group of
outpatient therapy clinics in the Baltimore area. He earned his BS, MA and DPT at
Northeastern University, Boston, MA

Ted is an experienced media and technology professional with over 25 years of experience in product management and content development. Ted has held various executive, editorial and product management roles at AOL Canada, Yahoo!, and 4INFO where he was Vice President of Products. Starting in 2010 Ted began working as an independent consultant for early-stage companies developing data, online video, and television products and was instrumental in starting RevUp.com, an award-winning company based in Northern California that revolutionized political and non-profit fundraising. Ted is currently working as the Vice President of Product at Propeller Health, one of the top digital health companies in the world that are helping bring connected devices to asthma and COPD patients around the world.

Derk Arts MD, PhD has over fifteen years of experience in medicine, research and technology. He founded Castor to solve the biggest issues in clinical research: a lack of inclusivity, patient focus and impact of data. Castor enables sponsors worldwide to run patient-centric trials on a unified platform, that helps them maximize the impact of research data on patient lives.

Dr. Derk Arts believes the key to achieving lasting change in the industry is through scalability and standardization. Technology to run better trials and maximize the impact of data should be available to all researchers.

Over the past 12 months, Castor provided pro-bono support to over 300 COVID-19 trials, and provided the entire infrastructure for the World Health Organizations’ Solidarity Trials.

Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain, developing innovative technologies to monitor and stimulate the brain to help many patients in need. She was nominated by IESE Business School as one of the most influential entrepreneurs under 40 in Spain in 2010. She received the EU Prize for Women Innovators from the European Commission EC in 2014. In 2015 & 2016, she was named one of the most inspiring women on the Inspiring Fifty list in Europe. Ana continues breaking the barriers of science and technology in an impactful way with Business Ethics.

Soňa is the CEO and co-founder of Mindpax, a company that brings personalized digital care to patients with severe mental illnesses. Mindpax’s DTX for bipolar disorder will be the first product of its kind offered under German DiGA. With a background in finance, Soňa has 7 years of experience with clinical validation of digital health products. She has been cooperating with European and American leading research institutes and opinion leaders. Her ambition is to keep bringing to market meaningful digital solutions that will change mental illness treatment from a guessing game into a data-driven, continuous, targeted care.

Veera is a hands-on technology executive and business leader with a passion to bring positive change through the power of data and AI. He created Constant Therapy, an award-winning mobile app that uses artificial intelligence to help tens of thousands of people living with neurological conditions regain essential life skills.

Veera also successfully built a number of innovative products at other startups, including at a company acquired by Apple that developed the world’s fastest digital signal processor. He began his career as a Lead Engineer at Motorola developing mobile software and hardware products, and later, as Vice President of Engineering at a startup acquired by Motorola, developed software products that are now used worldwide to manage wireless networks. Veera has six technology patents and recently won TiE Boston’s Entrepreneur of the Year Award. He is an expert mentor at MassChallenge HealthTech and Insight Data Sciences, is a Charter Member of TiE Boston, and is a guest lecturer for Entrepreneurship at Questrom School of Business. Veera holds a PhD in electrical and computer engineering and a Master of Science degree in physics from Northwestern University, as well as a bachelor’s degree from the Indian Institute of Technology in Bombay.

Mike Ravenscroft is a Manager with Dreamit Ventures Healthtech. Mike works with the fund’s digital health and medical device startups to accelerate their paths to commercialization and fundraising. He manages a national network of over 100 partners from industry, including leading health systems, insurance carriers, and pharmaceutical companies. Mike previously held investment roles at C5 Capital and CIT GAP Funds. He holds an MBA from the University of Maryland and a BA from the University of Michigan.